The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Afatinib monotherapy in patients with metastatic squamous cell carcinoma of the lung progressing after erlotinib/gefitinib (E/G) and chemotherapy: Interim subset analysis from a phase III trial.
Joo-Hang Kim
Research Funding - Boehringer Ingelheim
Francesco Grossi
Honoraria - Boehringer Ingelheim
Filippo De Marinis
No relevant relationships to disclose
Manuel Cobo
No relevant relationships to disclose
James Chih-Hsin Yang
Consultant or Advisory Role - Boehringer Ingelheim (U)
Honoraria - Boehringer Ingelheim
Yury Ragulin
No relevant relationships to disclose
Igor N. Bondarenko
No relevant relationships to disclose
Vikram K. Chand
Employment or Leadership Position - Boehringer Ingelheim
Bushi Wang
Employment or Leadership Position - Boehringer Ingelheim
Edith Gracien
Employment or Leadership Position - Boehringer Ingelheim
Martin H. Schuler
Consultant or Advisory Role - Boehringer Ingelheim
Research Funding - Boehringer Ingelheim; Roche